VolitionRx Limited Volition a multi-national epigenetics company, announces its first commercial sale of Volition's High Throughput Synthetic Sepsis method that measures Neutrophil Extracellular Traps ...

CAMBRIDGE, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the ...

1 Under the terms of the agreement, Altamira and its project collaboration partner intend to test in vitro and in vivo the use of nanoparticles with ... as amended, and Section 21E of the Securities ...

1 Under the terms of the agreement, Altamira and its project collaboration partner intend to test in vitro and in vivo the use of nanoparticles with ... as amended, and Section 21E of the Securities ...

Below is a detailed analysis of the two drugs secured by Cosmos Health. Abstract #1: ESTERS OF STEROIDAL LACTAM AND BIS (2-CHLOROETHYL) AMINOPHENOXY PROPANOIC ACID DERIVATIVES; Patent International ...

In preclinical in vivo studies of icovamenib in combination ... as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

In preclinical in vivo studies of icovamenib in combination with GLP-1-based ... as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as ...

Detailed price information for Biomea Fusion Inc (BMEA-Q) from The Globe and Mail including charting and trades.

For more information, please visit https://metagenomi.co. Cautionary Note Regarding Forward‐Looking Statements This press release contains “forward-looking statements” within the meaning of Section ...

Know Labs, Inc. is pleased to announce the official launch of its structured client engagement process for Know Labs Technology Licensing (KTL), ensuring a seamless pathway for corporations, ...

With vivo and Huawei growing (by 14% and 24%, respectively), both were breathing down Apple’s neck – both companies shipped 12.9 million units in Q4. For 2025, the analysts expect the ...